Business
BullFrog AI Announces Abstract Accepted for Presentation at 2026 ASCO Gastrointestinal Cancers Symposium
AI-driven precision-oncology analysis identifies patient subtypes with potential enhanced response to glufosfamide Accepted ASCO abstract, submitted in collaboration with Eleison Pharmaceuticals, provides further validation of BullFrog AI’s technology GAITHERSBURG, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enabl
About this update from Bullfrog Ai Holdings, Inc.
[{"type":"image","alt":"BullFrog AI Holdings, Inc.","displaySize":"","headline":null,"caption":"BullFrog AI Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/40a6d1d7288dd7624185c5755b024c0e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cckXAhHY1jCBABonzk6CjQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/40a6d1d7288dd7624185c5755b024c0e","width":300,"height":73}},"lazy":false},{"type":"text","content":"AI-driven precision-oncology analysis identifies patient subtypes with potential enhanced response to glufosfamide","length":114,"tagName":"p"},{"type":"text","content":"Accepted ASCO abstract, submitted in collaboration with Eleison Pharmaceuticals, provides further validation of BullFrog AI’s technology","length":136,"tagName":"p"},{"type":"text","content":"GAITHERSBURG, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (“AI”) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced that an abstract submitted in collaboration with Eleison Pharmaceuticals has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (ASCO GI), to be held January 8–10, 2026, in San Francisco, California.","length":623,"tagName":"p"},{"type":"text","content":"The abstract, titled “Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma,” will be featured in Poster Session B on January 9. It will also be published in the ASCO GI 2026 online proceedings and subsequently appear in the Journal of Clinical Oncology (JCO) supplement corresponding to the symposium.","length":337,"tagName":"p"},{"type":"text","content":"Co-authored by Richard Kim, MD, Service Chief of Medical Gastrointestinal Oncology and Senior Member in the Gastrointestinal Oncology Department at Moffitt Cancer Center, Nikolas Naleid, MD, PharmD, Hematology/Oncology Fellow at Moffitt Cancer Center, Eleison Pharmaceuticals and BullFrog AI, the study explores data-driven precision-oncology approaches to identify patient subtypes that may de...